These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31876585)

  • 1. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma.
    Zarei S; Wang Y; Jenkins SM; Voss JS; Kerr SE; Bell DA
    Am J Surg Pathol; 2020 Mar; 44(3):316-328. PubMed ID: 31876585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
    Vang R; Shih IeM; Kurman RJ
    Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
    Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
    Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
    Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
    Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Updates on histologic grading and pathogenesis of ovarian serous carcinomas].
    Shen Y; Yang F; Liu JS
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):507-10. PubMed ID: 22169636
    [No Abstract]   [Full Text] [Related]  

  • 8. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
    Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
    Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
    Dehari R; Kurman RJ; Logani S; Shih IeM
    Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.
    Hayashi Y; Sasaki H; Takeshita S; Nishikawa R; Nishikawa H; Arakawa A; Yamashita Y; Takahashi S; Sugiura-Ogasawara M
    Oncol Rep; 2014 Nov; 32(5):1815-9. PubMed ID: 25174456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
    Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
    Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
    Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
    Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
    Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular pathology of ovarian serous borderline tumors.
    Malpica A; Wong KK
    Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
    Wong KK; Tsang YT; Deavers MT; Mok SC; Zu Z; Sun C; Malpica A; Wolf JK; Lu KH; Gershenson DM
    Am J Pathol; 2010 Oct; 177(4):1611-7. PubMed ID: 20802181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.
    Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A
    Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
    BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.